Biocon gets USFDA nod for generic product

Biotechnology major Biocon on Thursday said its unit has received approval from the US health regulator to market a generic product.

Biocon Pharma, a subsidiary of the company, has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mycophenolic Acid, the company said in a regulatory filing.

The product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant and is available in 180mg and 360mg strengths.

This approval further adds to Biocon’s portfolio of vertically integrated complex drug products, the company noted.

  • Related Posts

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    New Delhi- IndiaAI on Thursday signed a memorandum of understanding (MoU) with the Indian Council of Medical Research (ICMR) to advance healthcare outcomes through the responsible and scalable application of…

    Illegal drug manufacturing racket busted in Baddi area

    In a major crackdown on the illegal drug trade, the Drugs Control Administration (DCA), Himachal Pradesh, on Friday busted a racket involved in the illicit manufacturing and storage of narcotic…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    IndiaAI, ICMR sign MoU to advance AI in healthcare

    Illegal drug manufacturing racket busted in Baddi area

    Illegal drug manufacturing racket busted in Baddi area

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

    Six Women Develop Serious Complications After C-Section

    Six Women Develop Serious Complications After C-Section

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

    Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected